Gyrate Atrophy of the Choroid and Retina
Launched by NATIONAL EYE INSTITUTE (NEI) · Nov 3, 1999
Trial Information
Current as of January 15, 2025
Completed
Keywords
ClinConnect Summary
Gyrate atrophy of the choroid and retina (GA) is a rare autosomal recessive chorioretinal degeneration characterized by myopia, cataract, varying degrees of night blindness, and progressive constriction of visual fields associated with chorioretinal atrophy resulting in blindness. The objectives of this protocol are threefold:
1. Document the natural history of gyrate atrophy.
2. Relate the clinical course to the gene defect to explore the genetic heterogeneity inherent in this disease.
3. Assess the clinical course and laboratory findings of the effects of an arginine-deficient diet. The ...
Gender
ALL
Eligibility criteria
- INCLUSION CRITERIA:
- • Patients must have hyperornithemia and a deficiency of OAT activity to enter the study.
About National Eye Institute (Nei)
The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials